Mechanism of impaired growth hormone secretion in patients with Cushing's disease
- PMID: 1519417
- DOI: 10.1530/acta.0.1270013
Mechanism of impaired growth hormone secretion in patients with Cushing's disease
Abstract
The function of the growth hormone-releasing hormone (GHRH)-growth hormone (GH) axis in Cushing's disease was studied by monitoring (a) the GH responses to GHRH loading and L-dopa loading, (b) the GHRH response to L-dopa loading, and (c) the daytime profiles of plasma GH concentration. GH release following GHRH and L-dopa was blunted in patients as compared to that in age-matched control subjects. However, GHRH release following L-dopa was similar in patients and controls. The plasma GH levels in four patients measured every 20 min by a highly sensitive immunoradiometric assay for GH showed pulsatile GH secretion at low levels during the observation period. These results indicate that GHRH release from the hypothalamus is preserved in patients with Cushing's disease, and support the hypothesis that glucocorticoid inhibits GH secretion by altering the hypothalamic somatostatin tone.
Similar articles
-
Growth hormone releasing hormone priming increases growth hormone secretion in patients with Cushing's syndrome.Clin Endocrinol (Oxf). 1993 Apr;38(4):399-403. doi: 10.1111/j.1365-2265.1993.tb00521.x. Clin Endocrinol (Oxf). 1993. PMID: 8319372
-
Pyridostigmine enhances even if it does not normalize the growth hormone responses to growth hormone-releasing hormone in patients with Cushing's disease.Horm Res. 1991;35(3-4):99-103. doi: 10.1159/000181882. Horm Res. 1991. PMID: 1806475 Clinical Trial.
-
Effect of withdrawal of somatostatin plus growth hormone (GH)-releasing hormone as a stimulus of GH secretion in Cushing's syndrome.Clin Endocrinol (Oxf). 2002 Dec;57(6):745-9. doi: 10.1046/j.1365-2265.2002.01662.x. Clin Endocrinol (Oxf). 2002. PMID: 12460324
-
Inhibition of growth hormone release after the combined administration of GHRH and GHRP-6 in patients with Cushing's syndrome.Clin Endocrinol (Oxf). 1994 Nov;41(5):649-54. doi: 10.1111/j.1365-2265.1994.tb01831.x. Clin Endocrinol (Oxf). 1994. PMID: 7828354
-
Glucocorticoids and the regulation of growth hormone secretion.Nat Rev Endocrinol. 2013 May;9(5):265-76. doi: 10.1038/nrendo.2013.5. Epub 2013 Feb 5. Nat Rev Endocrinol. 2013. PMID: 23381030 Review.
Cited by
-
Cushing's Syndrome Effects on the Thyroid.Int J Mol Sci. 2021 Mar 19;22(6):3131. doi: 10.3390/ijms22063131. Int J Mol Sci. 2021. PMID: 33808529 Free PMC article. Review.
-
Rare case of iatrogenic pan hypopituitarism.Indian J Clin Biochem. 2002 Jul;17(2):101-3. doi: 10.1007/BF02867980. Indian J Clin Biochem. 2002. PMID: 23105359 Free PMC article.
-
Systemic side-effects of topical corticosteroids.Indian J Dermatol. 2014 Sep;59(5):460-4. doi: 10.4103/0019-5154.139874. Indian J Dermatol. 2014. PMID: 25284850 Free PMC article.
-
Pituitary adenomas evade apoptosis via noxa deregulation in Cushing's disease.Cell Rep. 2022 Aug 23;40(8):111223. doi: 10.1016/j.celrep.2022.111223. Cell Rep. 2022. PMID: 36001971 Free PMC article.
-
A Florid Case of Iatrogenic Cushing's Syndrome Induced by Topical Steroid with Osteoporosis and Hypogonadism.Indian J Dermatol. 2015 Jul-Aug;60(4):420. doi: 10.4103/0019-5154.160514. Indian J Dermatol. 2015. PMID: 26288430 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical